On Friday, ITeos Therapeutics Inc (NASDAQ: ITOS) opened lower -1.87% from the last session, before settling in for the closing price of $9.61. Price fluctuations for ITOS have ranged from $8.53 to $18.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -23.53% over the last five years. Company’s average yearly earnings per share was noted -13.92% at the time writing. With a float of $28.08 million, this company’s outstanding shares have now reached $35.84 million.
The firm has a total of 157 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.49%, operating margin of -611.15%, and the pretax margin is -439.61%.
ITeos Therapeutics Inc (ITOS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ITeos Therapeutics Inc is 23.11%, while institutional ownership is 83.91%.
ITeos Therapeutics Inc (ITOS) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.9 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.2) by 0.3. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.92% per share during the next fiscal year.
ITeos Therapeutics Inc (NASDAQ: ITOS) Trading Performance Indicators
Check out the current performance indicators for ITeos Therapeutics Inc (ITOS). In the past quarter, the stock posted a quick ratio of 18.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.00, a number that is poised to hit -1.17 in the next quarter and is forecasted to reach -5.36 in one year’s time.
Technical Analysis of ITeos Therapeutics Inc (ITOS)
Analysing the last 5-days average volume posted by the [ITeos Therapeutics Inc, ITOS], we can find that recorded value of 0.83 million was better than the volume posted last year of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 53.48%. Additionally, its Average True Range was 0.65.
During the past 100 days, ITeos Therapeutics Inc’s (ITOS) raw stochastic average was set at 7.35%, which indicates a significant decrease from 46.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.29% in the past 14 days, which was lower than the 71.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.22, while its 200-day Moving Average is $13.28. Now, the first resistance to watch is $9.82. This is followed by the second major resistance level at $10.22. The third major resistance level sits at $10.63. If the price goes on to break the first support level at $9.01, it is likely to go to the next support level at $8.60. Now, if the price goes above the second support level, the third support stands at $8.20.
ITeos Therapeutics Inc (NASDAQ: ITOS) Key Stats
There are currently 36,123K shares outstanding in the company with a market cap of 344.38 million. Presently, the company’s annual sales total 12,600 K according to its annual income of -112,640 K. Last quarter, the company’s sales amounted to 35,000 K and its income totaled -7,130 K.
